Sponsors and partnerships
The Centre for Stem Cell Biology has a number of generous sponsors and partners that we collaborate with in many projects, please see below and click the individual names for more information:
PluriMes
PluriMes is an EC funded partnership between Universities, small to medium businesses (SMEs) and named researchers from both the public and private sector.
There are 12 partners in the consortium based across six European countries.
UK Regenerative Medicine Platform
The UK Regenerative Medicine Platform (UKRMP) is a £25M initiative that is addressing the key translational challenges of regenerative medicine.
Central to the Platform are five interdisciplinary and complementary research Hubs that collectively provide a national resource through the generation of new tools, protocols and resources that can be utilized by other UK research groups in both academia and industry.
Medical Research Council
The Medical Research Council improves human health through world-class medical research.
We fund research across the biomedical spectrum, from fundamental lab-based science to clinical trials, and in all major disease areas.
Our research has resulted in life-changing discoveries for over a hundred years.
Action On Hearing Loss
Action on Hearing Loss is the Royal national charity helping people confronting deafness, tinnitus and hearing loss to live the life they choose.
Our vision is to find a cure for hearing loss and tinnitus, and to develop medicines to protect hearing and prevent tinnitus so that nobody needs to be isolated.
Biotechnology and Biological Sciences Research Council
We are one of seven Research Councils that work together as Research Councils UK (RCUK).
We are funded by the Government's Department for Business, Innovation and Skills (BIS).
Our vision is to lead world-class 21st century bioscience, promoting innovation in the bioeconomy and realising benefits for society within and beyond the UK.
OTOSTEM
OTOSTEM has identified the principal technological hurdles for the development of cell-based and drug-based hearing loss therapies and addresses these hurdles in successive and systematic manner.
National Institute for Biological Standards
We play a major national and international role in assuring the quality of biological medicines through; developing standards and reference materials, product control testing & carrying out applied research.
UKRI Engineering and Physical Sciences Research Council
EPSRC is the main UK government agency for funding research and training in engineering and the physical sciences, investing more than £800 million a year in a broad range of subjects - from mathematics to materials science, and from information technology to structural engineering.
Yorkshire Cancer Research
Our vision is that every single person in every community in and around Yorkshire has the very best chance of living a long and healthy life with, without and beyond cancer.
We have committed to investing £100m over the next 10 years to tackle the region’s biggest cancer problems.
We will work in partnership with researchers, scientists and clinicians, the NHS, Public Health bodies and other charities to make life-changing improvements to cancer outcomes in Yorkshire.
website
National Council of Science and Technology, Mexico.
The objective is to deliver significant research funding for internationally competitive and innovative collaborative projects between researchers from Mexico and the UK that will allow the pursuit of shared research interests.
EuroStemCell
EuroStemCell is here to help European citizens make sense of stem cells. We provide independent, expert-reviewed information and road-tested educational resources on stem cells and their impact on society.
We’ve received funding from the European Union’s Horizon 2020 research and innovation programme.
Technobeat
The interdisciplinary TECHNOBEAT consortium consists of renowned experts from six European countries and Israel working in the fields of cell therapy, tissue engineering, stem cell processing and clinical translation.
Together we aim to provide new treatment options for patients suffering from heart failure due to the loss of heart muscle tissue following myocardial infarction (heart attack).